Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CFTR | P13569 | 1/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475358 | 0.90 | KDM4E (0.72) | KDM4EPOLBHSD17B10LMNAMAPT | |
| SCHEMBL5617518 | 0.89 | HTT (0.58) | KDM4EPOLBHSD17B10LMNAMAPT | |
| SCHEMBL6038511 | 0.82 | KDM4E (0.66) | KDM4EPOLBHSD17B10LMNAMAPT | |
| SCHEMBL6038390 | 0.81 | KDM4E (0.65) | KDM4EPOLBHSD17B10LMNAMAPT | |
| SCHEMBL6038850 | 0.80 | KMT2A (0.64) | KDM4EPOLBHSD17B10LMNAMAPT | |
| SCHEMBL2302031 | 0.80 | ALDH1A1 (0.78) | KDM4EPOLBHSD17B10MAPTMEN1 | |
| SCHEMBL14301181 | 0.80 | KDM4E (0.66) | KDM4EPOLBHSD17B10LMNAMAPT | |
| SCHEMBL3147811 | 0.80 | MAPT (0.78) | KDM4EPOLBMAPTMEN1KMT2A | |
| SCHEMBL13452267 | 0.80 | MAPT (0.78) | KDM4EPOLBMAPTMEN1KMT2A | |
| SCHEMBL6039123 | 0.80 | KDM4E (0.59) | KDM4EPOLBHSD17B10LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | claimed |
| EP-1660461-B1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| EP-1660461-B1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1660461-A1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021513-A1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | CCL2, CCL11, CCR2 | KDM4E 4607/4885POLB 1014/4885HSD17B10 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.